Save
Pregnancy reports and outcomes from multiple sclerosis patients primarily treated with peginterferon beta-1a and delayed-release dimethyl fumarate in Germany
Author(s): ,
G. Niemczyk
Affiliations:
Patient Communication, Biogen GmbH, Ismaning
,
Y. Begus-Nahrmann
Affiliations:
Audimedes GmbH, Göttingen
,
S. Herold
Affiliations:
Audimedes GmbH, Göttingen
,
M.-T. Grundler
Affiliations:
Patient Communication, Biogen GmbH, Ismaning
,
H. Rosenström
Affiliations:
Biogen GmbH, Ismaning, Germany
R. Sedlmeier
Affiliations:
Biogen GmbH, Ismaning, Germany
ECTRIMS Online Library. Mäurer M.
Oct 12, 2018; 229121
Mathias Mäurer
Mathias Mäurer
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Discussion Forum (0)
Rate & Comment (0)

Abstract: P1281

Type: Poster Sessions

Abstract Category: Therapy - Others

Background: Diagnosis of multiple sclerosis (MS) affects mostly women in a childbearing age. Even with the indication that MS itself does not adversely affect pregnancy outcomes, MS patients have many pregnancy-related concerns regarding the use of disease-modifying therapies (DMTs). The goal of this retrospective analysis was to evaluate the onset of pregnancy for patients exposed to delayed-release dimethyl fumarate (DMF) or peginterferon beta-1a (PEG) patients, in addition to analysing obstetrical outcomes after end of pregnancy.
Methods:
From February 2014 and September 2014 patients were recruited for a patient support program for DMF and PEG, respectively. All patients signed a written consent form. Contents and coaching frequency for the DMTs were adapted according to patient needs. A pregnancy form was completed upon patients' report of pregnancy and data from births and infants was collected after the expected date of the pregnancy outcome. Pregnancy forms and data of births until first of January 2018 were analysed.
Results:
As of April 2018, 259 DMF-exposed pregnancies and 198 PEG-exposed pregnancies were reported. As soon as pregnancy was confirmed, the DMT was stopped for the expectant mother. For 7 and 8 cases, the expectant father was using DMF and PEG, respectively. The median age at time of reported pregnancy for the expectant mother was 31.4 years. For half of all patients it was their first pregnancy. Data on 205 and 145 pregnancy outcomes was collected for DMF and PEG, respectively. Regarding DMF 83% of the MS patients gave birth to a live and healthy infant, 1% had live births with abnormalities, 9% spontaneous abortions, 4% voluntary abortions, 2.5% premature deliveries and 0.5% foetal deaths. For PEG pregnancies, there were 74.3% live and healthy births, 0.7% live births with abnormalities, 13.6% spontaneous abortions, 6.4% voluntary abortions, 3.6% were premature deliveries and 1.4% foetal deaths. Overall, 49% and 45% of the infants were females for DMF and PEG, respectively. Most of the MS patients breastfed for more than 1 month.
Conclusion:
The percentage of spontaneous abortions for MS patients exposed to DMF or PEG were in the normal range compared to the overall population. The sex distribution was also in the normal range as reported by the German birth register. DMF and PEG as disease-modifying therapies prior to and in early pregnancy appear to have no influence on the onset and outcome of pregnancies.
Disclosure: YBN, SHE: received funding for medical writing.
GN, MTG, HR, and RS: employees of and hold stock/stock options in Biogen.

Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings